Ferroptosis in Oral Cancer: Mechanistic Insights and Clinical Prospects
Cells · 27.10.2025 · 14 (21) · 1685
DOI: 10.3390/cells14211685 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 27.10.2025. Verfasst von Jaewang Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam 13488, Republic of Korea. Hauptthemen laut MEDLINE: Ferroptosis, Mouth Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation, has emerged as a pivotal vulnerability in oral squamous cell carcinoma (OSCC). This review provides an overview of ferroptosis mechanisms and their implications for OSCC pathobiology and therapy. OSCC cells exhibit heightened reliance on anti-ferroptotic defenses such as GPX4, SLC7A11, FSP1, and Nrf2, and disrupting these pathways suppresses tumor growth and restores sensitivity to chemotherapy, radiotherapy, and immunotherapy. Genetic and epigenetic regulators, including p53, PER1, circ_0000140, and STARD4-AS1, critically modulate ferroptotic sensitivity, while metabolic enzymes such as ACSL4, LPCAT3, and TPI1 link ferroptosis to cellular plasticity and resistance. Preclinical studies highlight the promise of small-molecule inhibitors, repurposed agents (e.g., sorafenib, artesunate, trifluoperazine), natural compounds (e.g., piperlongumine, Evodia lepta, quercetin), and nanomedicine platforms for targeted ferroptosis induction. We further address ferroptosis within the tumor microenvironment, highlighting its immunogenic and context-dependent dual roles, and summarize genomic and transcriptomic evidence linking ferroptosis-related genes to patient prognosis. Beyond cancer, ferroptosis also contributes to non-malignant oral diseases, including pulpitis, periodontitis, and infection-associated inflammation, where inhibitors may protect tissues. Despite these advances, clinical translation is constrained by the lack of safe ferroptosis inducers and validated biomarkers. Future research should focus on developing pharmacologically viable GPX4 inhibitors, refining biomarker-driven patient stratification, and designing multimodal regimens that combine ferroptosis induction with standard therapies while preserving immune and tissue integrity. Ferroptosis therefore represents both a mechanistic framework and a translational opportunity to reshape oral oncology and broader oral disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam 13488, Republic of Korea.
- Logsynk, Seoul 06153, Republic of Korea.
- Department of Biomedical Science, General Graduate School, CHA University, Pocheon 11160, Republic of Korea.
ORCID-Profile: Jaewang Lee, Jong-Lyel Roh
Förderung
- National Research Foundation of Korea
Zitieren
APA
Lee, J., & Roh, J. L. (2025). Ferroptosis in Oral Cancer: Mechanistic Insights and Clinical Prospects. Cells, 14(21), 1685. https://doi.org/10.3390/cells14211685
Vancouver
Lee J, Roh JL. Ferroptosis in Oral Cancer: Mechanistic Insights and Clinical Prospects. Cells. 2025;14(21):1685. doi:10.3390/cells14211685
BibTeX
@article{Lee2025,
author = {Lee, Jaewang and Roh, Jong-Lyel},
title = {Ferroptosis in Oral Cancer: Mechanistic Insights and Clinical Prospects},
journal = {Cells},
year = {2025},
volume = {14},
number = {21},
pages = {1685},
doi = {10.3390/cells14211685}
}
EUVIMED